Telomir Pharmaceuticals Inc
Company Profile
Business description
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
Contact
100 SE, 2nd Street
Suite 2000, No.1009
MiamiFL33131
USAT: +1 786 396-6723
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
The ASX data center stock flying under the radar
stocks
What did Morningstar subscribers buy and sell during June?
stocks
Australia’s largest gold miner downgraded on a falling gold price
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,025.90 | 24.70 | -0.27% |
| CAC 40 | 8,366.85 | 2.20 | 0.03% |
| DAX 40 | 25,147.03 | 32.78 | 0.13% |
| Dow JONES (US) | 52,508.27 | 9.63 | 0.02% |
| FTSE 100 | 10,529.39 | 31.10 | 0.30% |
| HKSE | 24,695.62 | 354.89 | 1.46% |
| NASDAQ | 26,107.01 | 233.83 | 0.90% |
| Nikkei 225 | 68,554.30 | 810.80 | 1.20% |
| NZX 50 Index | 13,595.52 | 55.70 | -0.41% |
| S&P 500 | 7,543.59 | 28.25 | 0.38% |
| S&P/ASX 200 | 8,830.30 | 26.70 | -0.30% |
| SSE Composite Index | 3,963.90 | 3.22 | -0.08% |